Tech Enhanced Investing

JSW Energy is trading at RS. 492.60, up by 5.30 points or 1.09% from its previous close of RS. 487.30 on the BSE.

The stock opened at RS. 494.60 and has touched an intraday high of RS. 497.00 and a low of RS. 482.10. A total of 1,28,789 shares have changed hands on the counter so far.

A BSE group 'A' stock with a face value of RS. 10, JSW Energy touched a 52-week high of RS. 804.95 on September 24, 2024, and a 52-week low of RS. 419.10 on February 17, 2025. Over the past week, it recorded a high of RS. 497.00 and a low of RS. 470.55. The company's current market capitalization is RS. 85,815.43 crore.

Promoter holding in the company stands at 69.26%, while institutions hold 24.37% and non-institutional investors account for 6.37%.

JSW Energy’s Board of Directors, at its meeting held on May 15, 2025, approved a proposal to raise up to RS. 10,000 crore in one or more tranches. The fundraising may be conducted through private offerings, preferential allotments, qualified institutional placements, or other permitted methods, subject to necessary regulatory and statutory approvals.

Part of the diversified JSW Group, JSW Energy is a fast-growing power company with interests in carbon steel, power, mining, industrial gases, port infrastructure, aluminium, cement, and information technology.

Brigade Enterprises is currently trading at RS. 1104.05, up by 39.35 points or 3.70% from its previous close of RS. 1064.70 on the BSE.

The stock opened at RS. 1070.00 and hit an intraday high of RS. 1120.00 and a low of RS. 1056.85. A total of 4116 shares have been traded so far.

A BSE group 'A' stock with a face value of RS. 10, Brigade Enterprises touched a 52-week high of RS. 1451.90 on June 25, 2024, and a 52-week low of RS. 812.85 on April 7, 2025. Over the past week, the scrip recorded a high and low of RS. 1120.00 and RS. 1025.05, respectively. The company’s market capitalization now stands at RS. 27034.91 crore.

Promoters hold a 41.14% stake in the company, while institutional and non-institutional investors hold 43.08% and 15.78% respectively.

For the quarter ended March 31, 2025, Brigade Enterprises reported a 29.69% year-on-year rise in standalone net profit at RS. 208.04 crore compared to RS. 160.41 crore in the same quarter last year. However, its total income declined by 25.52% to RS. 683.82 crore from RS. 918.07 crore in Q4FY24.

On a consolidated basis, net profit rose by 18.25% to RS. 249.35 crore in Q4FY25 from RS. 210.86 crore in the corresponding quarter of the previous year. Total income, however, fell by 13.07% to RS. 1,532.29 crore compared to RS. 1,762.62 crore in Q4FY24.

For the full financial year ended March 31, 2025, standalone net profit surged 43.09% to RS. 455.30 crore from RS. 318.19 crore a year earlier. Total income for the year rose 7.20% to RS. 2,384.06 crore, up from RS. 2,224.00 crore in FY24.

On a consolidated level, the company posted a 69.68% jump in net profit at RS. 680.47 crore for FY25, compared to RS. 401.04 crore in FY24. The total consolidated income increased by 4.92% to RS. 5,313.54 crore from RS. 5,064.15 crore in the previous year.

Medico Remedies is currently trading at RS. 54.74, up by 1.52 points or 2.86% from its previous close of RS. 53.22 on the BSE.

The stock opened at RS. 52.20 and has recorded a high and low of RS. 54.74 and RS. 52.20 respectively. A total of 6018 shares have been traded so far.

Classified under BSE group 'B', the stock has a face value of RS. 2 and has touched a 52-week high of RS. 79.78 on February 6, 2025, and a 52-week low of RS. 35.00 on June 5, 2024. Over the past week, the scrip has traded between RS. 56.00 and RS. 50.33. The company currently holds a market capitalization of RS. 453.26 crore.

The promoter shareholding stands at 63.79%, while institutional and non-institutional investors hold 0.13% and 36.08% respectively.

Medico Remedies has commenced the construction of a new manufacturing facility for producing B lactam tablets, capsules, dry syrups, and injections, including formulations like amoxycillin and clavulanic acid. The upcoming plant will have a production capacity of 25 million tablets, 45 million capsules, 10 million dry syrups, and 10 million injectables. The total investment for this expansion is estimated at RS. 30 crore, and the full capacity is expected to be operational within 2 years.

The facility is being developed in accordance with PIC/S (Pharmaceutical Inspection Co-operation Scheme) guidelines and is projected to add approximately RS. 25 crore in annual revenue upon receiving all necessary approvals.

Medico Remedies is a prominent manufacturer and exporter of pharmaceutical formulations such as tablets, capsules, and suspensions.

Ahasolar Technologies is trading at RS 113.95, up by 2.20 points or 1.97% from its previous close of RS 111.75 on the BSE.

The stock opened at RS 113.95 and recorded the same as its high and low for the day. So far, 400 shares have been traded on the counter.

Classified under the BSE group 'MT' with a face value of RS 10, the stock has seen a 52-week high of RS 537.45 on July 29, 2024, and a 52-week low of RS 85.65 on April 1, 2025. Over the past week, it has moved between RS 113.95 and RS 109.20. The company's current market capitalization stands at RS 34.44 crore.

Promoters hold a 36.95% stake in the company, while non-institutional investors account for 63.05%.

In a recent development, Ahasolar Technologies has received a work order from the Gujarat Urban Development Company (GUDA) for consultancy services across 48 locations. The scope includes preparing pre-feasibility reports, conducting site surveys, technical assessments, and financial analysis for setting up grid-connected solar photovoltaic projects across various locations in Gujarat. The order is valued at approximately RS 11.76 lakh and is to be executed within four months.

Ahasolar Technologies operates in the CleanTech sector, promoting energy transition through digital transformation and supporting the widespread adoption of renewable energy solutions.

JK Tyre & Industries is trading at RS. 348.05, up by 7.70 points or 2.26% from its previous close of RS. 340.35 on the BSE.

The stock opened at RS. 342.05 and moved between a high of RS. 350.10 and a low of RS. 340.00. A total of 23,337 shares have changed hands so far.

A BSE Group 'A' stock with a face value of RS. 2, JK Tyre has recorded a 52-week high of RS. 510.90 on July 15, 2024, and a 52-week low of RS. 231.65 on April 7, 2025. Over the past week, the scrip traded between RS. 350.10 and RS. 328.90. The company’s current market capitalization stands at RS. 9579.74 crore.

Promoter holding in the company is at 50.55%, while institutions and non-institutional investors hold 21.97% and 27.48%, respectively.

JK Tyre has commenced production of passenger car tyres using ISCC Plus certified sustainable raw materials at its Chennai-based plant. The company has started manufacturing UX Royale Green tyres, marking a significant step toward environmentally responsible innovation. Notably, JK Tyre was the world’s first tyre manufacturer to receive ISO 9001 certification across its operations in 1995.

JK Tyre & Industries is engaged in the manufacturing and marketing of automotive tyres, tubes, and flaps.

Berger Paints India is currently trading at RS. 564.75, up by 10.95 points or 1.98% from its previous closing of RS. 553.80 on the BSE.

The stock opened at RS. 560.00 and has touched an intraday high of RS. 580.00 and a low of RS. 560.00. So far, 46,078 shares have been traded on the exchange.

This BSE group 'A' stock, with a face value of RS. 1, recorded a 52-week high of RS. 629.60 on September 17, 2024, and a 52-week low of RS. 437.80 on December 30, 2024. In the past week, the scrip has moved between RS. 580.00 and RS. 520.00. The current market capitalization stands at RS. 67,126.39 crore.

Promoters hold 74.98% of the company’s shares, while institutional investors and non-institutions hold 15.84% and 9.17% respectively.

On the financial front, Berger Paints India reported a 30.47% year-on-year jump in net profit to RS. 236.92 crore for the quarter ended March 31, 2025, compared to RS. 181.59 crore in the same quarter last year. The company’s total income rose 4.61% to RS. 2,366.90 crore in Q4FY25, up from RS. 2,262.58 crore in Q4FY24.

On a consolidated basis, Q4 net profit rose 18.10% to RS. 262.91 crore, compared to RS. 222.62 crore in the year-ago quarter. Consolidated income increased 7.29% to RS. 2,721.14 crore from RS. 2,536.16 crore.

For the full year ended March 31, 2025, standalone net profit grew 6.15% to RS. 1,077.50 crore from RS. 1,015.05 crore in FY24, while total income increased by 2.30% to RS. 10,291.43 crore from RS. 10,060.37 crore.

On a consolidated basis, full-year net profit rose slightly by 1.11% to RS. 1,182.81 crore from RS. 1,169.82 crore, and total income rose 3.35% to RS. 11,639.49 crore from RS. 11,262.60 crore.

Kesar India is trading at RS. 669.50, up by 20.15 points or 3.10% from its previous close of RS. 649.35 on the BSE.

The stock opened at RS. 675.00 and has recorded a high of RS. 675.20 and a low of RS. 660.00 so far. A total of 1400 shares have been traded on the counter.

This BSE group 'M' stock, with a face value of RS. 10, touched its 52-week high of RS. 1143.25 on September 30, 2024, and its 52-week low of RS. 476.00 on March 11, 2025. In the past week, the stock traded between RS. 698.70 and RS. 640.00. The company’s current market capitalization stands at RS. 1631.04 crore.

The promoter holding in the company is 74.99%, with institutional investors holding 18.22% and non-institutional investors holding 6.79%.

Kesar India has acquired a 30% stake in Trinity Buildcorp LLP, a Limited Liability Partnership incorporated on May 14, 2025. The strategic investment aims to diversify Kesar India's operations into construction and real estate activities.

Trinity Buildcorp LLP will engage in activities such as real estate development, construction of residential and commercial properties, acquisition and management of land and buildings, and other related infrastructure development projects. It will also focus on leasing, renovation, and administration of properties, as well as collaborations with builders, tenants, and developers both in India and internationally.

Kesar India is already active in developing and constructing residential and commercial plots, industrial buildings, colonies, mills, factory structures, and workshops.

Kalpataru Projects International is trading at RS. 1044.75, marking a rise of 24.25 points or 2.38% from its previous close of RS. 1020.50 on the BSE.

The stock opened at RS. 1060.05 and recorded an intraday high of RS. 1065.00 and a low of RS. 1031.35. A total of 20,462 shares have been traded so far.

A BSE group 'A' stock with a face value of RS. 2, Kalpataru Projects hit a 52-week high of RS. 1449.15 on September 6, 2024, and a 52-week low of RS. 770.05 on April 7, 2025. Over the past week, the stock has moved between RS. 1065.00 and RS. 905.05. The company’s market capitalization now stands at RS. 17,855.12 crore.

The company’s shareholding pattern includes 33.52% held by promoters, 56.64% by institutional investors, and 9.85% by non-institutional investors.

Kalpataru Projects International, along with its global subsidiaries, has secured new orders and notifications of awards worth approximately RS. 2,372 crore. These orders include contracts in the Power Transmission & Distribution (T&D) segment in both Indian and international markets, as well as projects in the Buildings and Factories (B&F) segment within India.

Kalpataru Projects is one of India’s leading and fastest-growing EPC (Engineering, Procurement and Construction) companies, with operations spanning power transmission & distribution, oil & gas pipelines, railways, infrastructure, civil contracting, and warehousing & logistics. The company also maintains a strong international presence in the power T&D sector.

Shilpa Medicare is currently trading at RS 706.95, up by 12.80 points or 1.84% from its previous close of RS 694.15 on the BSE.

The stock opened at RS 700.05 and has touched an intraday high of RS 725.25 and a low of RS 700.05. A total of 6204 shares have been traded so far.

The BSE Group 'A' stock with a face value of RS 1 has registered a 52-week high of RS 959.95 on September 18, 2024, and a 52-week low of RS 419.10 on June 4, 2024. Over the last week, the stock traded between RS 725.25 and RS 603.00. The company's current market capitalization stands at RS 7017.96 crore.

Promoters hold 44.23% of the company's shares, while institutional and non-institutional investors hold 18.52% and 37.25% respectively.

The United States Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) to Shilpa Medicare’s 100% subsidiary, Shilpa Pharma Lifesciences’ Unit-1. The site has been classified as "Voluntary Action Indicated" (VAI) following an inspection conducted from March 3 to March 7, 2025.

Shilpa Medicare is known for manufacturing and exporting high-quality Active Pharmaceutical Ingredients (APIs), fine chemicals, intermediates, herbal products, and specialty chemicals, adhering strictly to international standards and utilizing advanced technologies.

Abans Enterprises is currently trading at RS. 30.60, up by 0.67 points or 2.24% from its previous close of RS. 29.93 on the BSE.

The stock opened at RS. 32.49 and touched a high and low of RS. 32.49 and RS. 30.51 respectively. A total of 7357 shares have been traded so far.

This BSE group 'X' stock with a face value of RS. 2 has seen a 52-week high of RS. 45.40 on October 21, 2024, and a 52-week low of RS. 22.40 on May 23, 2024. In the past week, the stock has moved between RS. 32.49 and RS. 25.25. The company’s current market capitalization stands at RS. 213.43 crore.

Promoters hold a majority stake of 74.56% in the company, while institutional and non-institutional investors hold 11.48% and 13.96% respectively.

The Board of Directors, in its meeting held on May 14, 2025, approved raising funds up to RS. 1,000 crore through the issuance of debt securities or other non-convertible securities on a private placement basis. These may be listed or unlisted and issued in one or more tranches, subject to necessary shareholder and regulatory approvals.

Abans Enterprises is engaged in the trading, processing, broking, and consulting of various commodities, including agricultural products, base and precious metals, stones, and also operates in commodities, shares, and derivatives through electronic exchanges.